El ipilimumab (Yervoy) para el cáncer de próstata - segunda línea

Autores
Categoría Resumen estructurado de revisiones sistemáticas
RevistaHTA Database
Año 2012
RECORD STATUS: This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. CITATION: NHSC. Ipilimumab (Yervoy) for prostate cancer – second line Birmingham: National Horizon Scanning Centre (NHSC). Horizon Scanning Review. 2011
Epistemonikos ID: 02a9bfdf96a2891516bbdac753e2812b109562a0
First added on: Feb 06, 2015